Index of drugs

Emergencies in the course of arterial hypertension, e.g. hypertensive crisis, severe and very severe forms of arterial hypertension, hypertension resistant to pharmacological treatment. Controlled lowering of blood pressure in case of increased pressure during and (or) after surgery.

5 ml of solution contains 25 mg of urapidil in the form of hydrochloride.

Preparation with hypotensive effect. It lowers systolic and diastolic blood pressure by reducing peripheral resistance. Urapidyl works centrally and peripherally. Peripherally: mainly blocking postsynaptic receptors a₁ and in this way inhibits the vasoconstrictive effect of catecholamines. Centrally: modulates the activity of circulatory regulation centers, preventing reflex stimulation or inhibition of the sympathetic nervous system. It binds 80% of plasma proteins. It is metabolized in the liver and excreted in urine at 50-70% (15% in unchanged form) and faeces, mainly in the form of metabolites. T_0,5 after rapid intravenous administration is 2.7 hours. In elderly patients and patients with advanced renal and / or renal failure the volume of distribution and clearance is reduced and the half-life is prolonged.

Hypersensitivity to the components of the preparation. Narrowing of the aortic tract or arteriovenous fistula (except haemodynamically inactive haemodialysis fistula).

Particularly cautiously used in patients with heart failure due to mechanical damage (eg aortic or mitral stenosis), pulmonary embolism or impaired cardiac activity for peripheral reasons, in patients with impaired hepatic function and moderate or severe renal impairment ( it may be necessary to reduce the dose). In elderly patients, lower doses should be used initially because of the changed sensitivity. If another blood pressure-lowering medicine has been previously administered, wait for the effect of the product on the pressure to be visualized, and then reduce the urapidil dose (an excessively fast drop in blood pressure can lead to bradycardia or cardiac arrest). Caution should be exercised in patients treated concomitantly with cimetidine. The safety of use in children has not been established.

Due to the lack of sufficient data, use is not recommended during pregnancy unless the potential benefits to the mother outweigh the risks to the fetus. Animal studies have not yet shown a harmful effect on the fetus. It is not known whether urapidil is excreted in human milk, therefore breastfeeding should not be used during treatment.

Common: nausea, pain and dizziness. Uncommon: palpitations, tachycardia or bradycardia, tightness of the bridge, dyspnoea, symptoms resembling angina, orthostatic hypotension, vomiting, fatigue, irregular heart action, sudden sweating. Rarely: priapism, nasal congestion, hypersensitivity reactions (pruritus, redness of the skin, rash). Very rare: anxiety, a reduction in the number of platelets. Not known: angioneurotic edema, urticaria.

Intravenously.Emergencies in the course of arterial hypertension, e.g. hypertensive crisis, severe and very severe forms of arterial hypertension, hypertension resistant to pharmacological treatment10-50 mg of the preparation as an injection into a vein with simultaneous monitoring of blood pressure; the pressure reduction usually takes place within 5 min .; depending on the patient's response, the dose can be repeated. In order to maintain the level of pressure obtained after the infusion administration, 250 mg of the preparation is administered in 500 ml of 0.9% NaCl, 5% or 10% Glucose (infusion rate: on average 9 mg / h depending on the patient's response to the drug); if the maintenance dose is administered using an infusion pump, 100 mg of the preparation should be dissolved in 0.9% NaCl, 5% or 10% Glucose, so as to obtain 50 ml of the solution; the maximum concentration of urapidil in the infusion solution must not exceed 4 mg / ml; the recommended initial rate of administration is 2 mg / min.Controlled lowering of blood pressure in case of increased pressure during and (or) after surgery: 25 mg of the preparation by intravenous injection; if after 2 min. there will be a reduction in pressure, the pressure should be maintained at a reduced level by continuous infusion (6 mg of urapidil for 1-2 min., then the dose should be reduced); if after 2 min. there will be no reduction in blood pressure, 25 mg of the preparation should be given by intravenous injection. If after the second dose after 2 min. there will be a reduction in pressure, it should be maintained at a reduced level by continuous infusion (6 mg of urapidil for 1-2 min., then the dose should be reduced); if after 2 min. no hypotension should be given 50 mg of the preparation by intravenous injection. If the blood pressure drops after the third dose, the pressure should be kept low by continuous infusion (6 mg urapidil for 1-2 min., Then the dose should be reduced). The patient must be in a supine position during administration. The treatment with the preparation may last 7 days; treatment can be repeated if the blood pressure is raised again.